Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Chlamydia Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Chlamydia Infections - Pipeline Review, H2 2014', provides an overview of the Chlamydia Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chlamydia Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chlamydia Infections Overview 7 Therapeutics Development 8 Pipeline Products for Chlamydia Infections - Overview 8 Pipeline Products for Chlamydia Infections - Comparative Analysis 9 Chlamydia Infections - Therapeutics under Development by Companies 10 Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes 11 Chlamydia Infections - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Chlamydia Infections - Products under Development by Companies 14 Chlamydia Infections - Products under Investigation by Universities/Institutes 15 Chlamydia Infections - Companies Involved in Therapeutics Development 16 Abera Bioscience AB 16 Adamis Pharmaceuticals Corporation 17 CEL-SCI Corporation 18 Cubist Pharmaceuticals, Inc. 19 Genocea Biosciences, Inc. 20 Osel Inc. 21 Chlamydia Infections - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 acALY-18 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 C-31G - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CEL-1000 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 chlamydia vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 chlamydia vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 chlamydia vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 chlamydia vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 chlamydia vaccines - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Cyanovirin-N for Infectious Disease - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Drugs to Block Virulence for Chlamydia Infections - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Drugs to Inhibit CPAF for Chlamydia Infections - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 GEN-001 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules for Chlamydophila Infections - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules to Target Heparan Sulfate for Bacterial and Viral Infections - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 solithromycin - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Chlamydia Infections - Recent Pipeline Updates 49 Chlamydia Infections - Dormant Projects 57 Chlamydia Infections - Product Development Milestones 58 Featured News & Press Releases 58 Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 58 Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria 58 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 61 Disclaimer 61
List of Tables Number of Products under Development for Chlamydia Infections, H2 2014 8 Number of Products under Development for Chlamydia Infections - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2014 16 Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 17 Chlamydia Infections - Pipeline by CEL-SCI Corporation, H2 2014 18 Chlamydia Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 19 Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H2 2014 20 Chlamydia Infections - Pipeline by Osel Inc., H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Chlamydia Infections Therapeutics - Recent Pipeline Updates, H2 2014 49 Chlamydia Infections - Dormant Projects, H2 2014 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.